EMBARQ-CSU2
52 evidence topics · 7 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Official title in the ClinicalTrials.gov record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Active, not recruiting” (opens the source at this quote in a new tab)
“Study Start (Actual) 2024-07-19” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-08-04” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-06” (opens the source at this quote in a new tab)
“First Posted 2024-06-12” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-12” (opens the source at this quote in a new tab)
Number of locations and EU trial number in the ClinicalTrials.gov record
Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2
Data cutoff for the topline results
Treatment continuing to 52 weeks with 16 weeks of follow-up
Study design
Study periods in the ClinicalTrials.gov record
Randomization ratio and study periods in the topline presentation
Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release
Placebo for 52 weeks and 16-week follow-up in the Form 10-Q
Timing of the primary endpoint analysis at 24 weeks
Entry into the phase 3b long-term extension after the trial
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
“Women who are pregnant or nursing.” (opens the source at this quote in a new tab)
“Other diseases associated with urticaria.” (opens the source at this quote in a new tab)
“Active pruritic skin condition in addition to CSU.” (opens the source at this quote in a new tab)
“Known HIV, hepatitis B or hepatitis C infection.” (opens the source at this quote in a new tab)
“History of anaphylaxis” (opens the source at this quote in a new tab)
“Prior treatment with barzolvolimab” (opens the source at this quote in a new tab)
Population summarized in the topline presentation
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |
Arms with loading doses in the topline presentation
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record
Secondary outcome measures in the current ClinicalTrials.gov record
“Percentage of patients with UAS7=0 at Week 12” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)
“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)
“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)
Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history
“Comparing V1 (2024-06-07) to V18 (2026-02-03)” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 4” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 24” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 = 0 at Week 24” (opens the source at this quote in a new tab)
Key secondary endpoints at Week 12 in the topline presentation
Complete response (UAS7=0) as the treatment goal stated by the company
Reason given by the company for presenting complete response at Week 24
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment per trial at initiation
Actual enrollment in the ClinicalTrials.gov record
Participants randomized in the topline release
Description of analysis sets
Adjusted proportions from logistic regression with multiple imputation
Definition of the omalizumab-refractory subpopulation
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
| Characteristic | Placebo every 4 weeks (N=321) | Barzolvolimab 150 mg every 4 weeks (N=324) | Barzolvolimab 300 mg every 8 weeks (N=321) |
|---|---|---|---|
| Age (years), mean (SD) | “45.7 (14.59)” | “46.2 (14.53)” | “46.2 (14.01)” |
| Female, n (%) | “215 (67.0)” | “229 (70.7)” | “208 (64.8)” |
| Race, White, n (%) | “229 (71.3)” | “225 (69.4)” | “242 (75.4)” |
| Race, Black, n (%) | “6 (1.9)” | “11 (3.4)” | “8 (2.5)” |
| Race, Asian, n (%) | “49 (15.3)” | “54 (16.7)” | “50 (15.6)” |
| Weight (kg), mean (SD) | “80.70 (18.96)” | “78.72 (19.10)” | “79.94 (19.15)” |
| UAS7 score, mean (SD) | “29.3 (7.19)” | “29.7 (6.87)” | “29.6 (7.28)” |
| Severe disease (UAS7 of 28 or more), n (%) | “199 (62.0)” | “203 (62.7)” | “198 (61.7)” |
| Omalizumab refractory, n (%) | “43 (13.4)” | “44 (13.6)” | “42 (13.1)” |
| AAS7 greater than 0, n (%) | “206 (64.2)” | “213 (65.7)” | “217 (67.6)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “50.2 (28.63)” | “51.5 (28.67)” | “51.7 (27.81)” |
| DLQI score, mean (SD) | “14.2 (7.11)” | “14.4 (7.02)” | “14.3 (7.11)” |
Efficacy results
Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error
| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
|---|---|---|
| Placebo every 4 weeks | “29.3” | “-11.4 (0.64)” |
| Barzolvolimab 150 mg every 4 weeks | “29.7” | “-20.2 (0.63) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “29.6” | “-19.7 (0.64) (p<.00001)” |
Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set
“Treatment Difference LS Mean (97.5% CI):” (opens the source at this quote in a new tab)
“Full analysis set; imputed data and MMRM model” (opens the source at this quote in a new tab)
| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
|---|---|---|
| Barzolvolimab 150 mg every 4 weeks | “-8.9 ( -10.9, -6.9)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-8.3 ( -10.4, -6.3)” | “p < .00001” |
Complete response (UAS7=0) at Week 12, adjusted proportions
| Arm | Complete response (UAS7=0) at Week 12 |
|---|---|
| Placebo every 4 weeks | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “45.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.0% (p<.00001)” |
Complete response (UAS7=0) at Week 24 presented by the company
| Arm | Complete response (UAS7=0) at Week 24 |
|---|---|
| Placebo every 4 weeks | “17.6%” |
| Barzolvolimab 150 mg every 4 weeks | “54.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “48.4% (p<.00001)” |
Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants
| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
|---|---|
| Placebo every 4 weeks | “15.1%” |
| Barzolvolimab 150 mg every 4 weeks | “41.7% (p=.0089)” |
| Barzolvolimab 300 mg every 8 weeks | “46.4% (p=.0036)” |
AAS7=0 at Week 12 in participants with baseline AAS7>0
| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
|---|---|
| Placebo every 4 weeks | “33.7%” |
| Barzolvolimab 150 mg every 4 weeks | “74.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.2% (p<.00001)” |
Other key secondary endpoints at Week 12 reported as met without values
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety statement through the 24-week placebo-controlled period
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
|---|---|---|---|
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |
Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
“AG3 anaphylaxis adjudicated as unlikely” (opens the source at this quote in a new tab)
“BG2 angioedema/throat tightness/urticaria” (opens the source at this quote in a new tab)
“CG3 anemia/neutropenia;” (opens the source at this quote in a new tab)
“G2 malaise/dyspnea/chest pain;” (opens the source at this quote in a new tab)
Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Study limitations
Summary: limitations of the available EMBARQ-CSU2 evidence
- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-06-07) with version 18 (2026-02-03) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (17.6%, 54.0%, and 48.4%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Participant counts are reported from different sources without reconciliation: 976 participants randomized (release) and enrolled (ClinicalTrials.gov), and a full analysis set of N=321, N=324, and N=321 by arm (presentation). The placebo duration also differs: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”. Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 14.2, 14.4, and 14.3), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 43, 44, and 42 participants (13.4%, 13.6%, and 13.1% of each arm), with p-values of .0089 and .0036 for UAS7=0 at Week 12 in this subgroup. The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.